There are five or seven types of myeloma, depending on the modality. Myeloma has a survival period of about six months without any treatment. If active and effective treatment is carried out survival can reach 5-10 years or even higher. There are two main ways to classify myeloma. The general typing can be divided into 5 types, including isolated, multiple, diffuse, extramedullary, and leukemic types. According to the classification of immunoglobulins, it is divided into 7 types. IgG type is common, accounting for 50%-60% of all myeloma cases, and is prone to infection, hypercalcemia and amyloidosis; IgA type accounts for 25% of the incidence, and also has obvious hypercalcemia and a tendency to have coagulation abnormalities and intracranial hemorrhage in combination with amyloidosis, with a poor prognosis; IgD type is rare, accounting for only about 1% of the cases, and the tumor cells are poorly differentiated and prone to intracranial hemorrhage. IgD type is rare, accounting for only about 1%, with poorly differentiated tumor cells, easily complicated by plasma cell leukemia, almost 100% combined with renal impairment, and a relatively short survival period; IgM type is rare, prone to hyperviscosemia or Raynaud’s phenomenon; light chain type accounts for about 20%, with more than 80% having Benignan proteinuria, easily combined with renal failure and amyloidosis, with a very poor prognosis; IgE type is rare; non-secretory type accounts for less than 1%, with no abnormal immunoglobulin in blood and urine. There is no abnormal immunoglobulin in the urine, and there is an increase of plasma cells in the bone marrow with osteolytic changes or diffuse osteoporosis. Early detection, diagnosis and treatment are the keys to cure bone marrow cancer and prolong life expectancy. Late stage patients should actively cooperate with doctors’ treatment and maintain an optimistic attitude to reduce symptoms and improve patients’ survival quality.